2022, Vol. 6 Issue 1, Part APages: 01-05
Understanding urticaria, and their management: An appraisal
Dr. Md. Gheyasuddin, Dr. Khalid Eqbal and Dr. Md. Najmuddin
Viewed: 262 - Downloaded: 132
Urticaria, or hives, is a common skin and mucous membrane illness characterized by erythematous, edematous, irritating, and transitory plaques. It affects roughly 20% of people at some point in their lives. It can produce substantial discomfort, last for months to years, and seldom reflect a major systemic disease or life-threatening allergic reaction, despite being self-limited and benign. In the Unani system of medicine urticaria is labeled as Shara, Avicenna, defined that Shara is a Damwi (sanguineous) disease usually but it may also be due to Safravi Khoon (bilious blood) or Balgham Boraqi (acidic phlegm). Urticaria is induced by the release of histamine and other inflammatory mediators from mast cells and basophils mediated by immunoglobulin E and non-immunoglobulin E. Anaphylaxis must be ruled out before a diagnosis can be made. In 80 percent to 90 percent of instances, chronic urticaria is idiopathic. Treatment with H1 antihistamines and, in certain circumstances, short-term systemic corticosteroids is favored; H2 antagonists may be added in refractory cases, however additional treatment options, including omalizumab, cyclosporine, and leukotriene receptor antagonists, may be examined during missed occurrences. Unani Medicine has its own framework for treating patients based on treatment principles which include; Ilja Bil Ghiza, Ilaj Bit Tadbeer, and Ilaj Bil Dawa.
How to cite this article:
Dr. Md. Gheyasuddin, Dr. Khalid Eqbal, Dr. Md. Najmuddin. Understanding urticaria, and their management: An appraisal. Int J Unani Integ Med 2022;6(1):01-05.